Creating safer and more effective alternatives to erythropoietin for treating anemia
Official title: Designing safe, potent, and cost-effective small peptide erythropoietin analogs
Funded at Covenant Therapeutics, LLC · NIH-10602271 · Data updated 2026-11-12
This study is working on a new, easier, and safer treatment for anemia, especially for people with kidney disease and cancer, by creating a special version of a hormone that helps make red blood cells, so you won't have to deal with as many injections or side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Covenant Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | September 10, 2023 |
| Project end | September 9, 2025 |
| Funding year | 2023 |
| Award (this year) | $249,965 |
| NIH project number | 1R43HL167440-01 |
| Project ID | NIH-10602271 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from anemia due to chronic kidney disease or malignancies.
✕Less likely to help
Patients who do not have anemia or those whose anemia is not related to kidney disease or cancer may not benefit from this research.
What this research studies
This research focuses on developing new small peptide analogs of erythropoietin, a hormone that stimulates red blood cell production, to treat anemia, particularly in patients with kidney disease and cancer. The goal is to create a treatment that is not only more affordable but also safer and easier to administer than current therapies, which often require frequent injections and can lead to complications. The researchers will optimize these peptide analogs to ensure they are stable and effective for weekly dosing, using animal models to test their efficacy and safety. This innovative approach aims to reduce the risk of adverse effects associated with existing treatments.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer, more convenient, and cost-effective treatment option for anemia.
How similar studies have gone: Previous research has shown promise in developing peptide analogs for erythropoietin, indicating potential for success in this novel approach.
Where this research is happening
-
Covenant Therapeutics, LLC
Charlottesville, United States Active
Researchers
- Principal investigator: Gineste, Cyrille — Covenant Therapeutics, LLC
- Study coordinator: Gineste, Cyrille
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.